LEFKOFF KYLE 4
4 · ARRAY BIOPHARMA INC · Filed Jul 6, 2018
Insider Transaction Report
Form 4
LEFKOFF KYLE
Director
Transactions
- Exercise/Conversion
Common Stock
2018-07-06$5.95/sh+25,000$148,750→ 67,720 total - Sale
Common Stock
2018-07-06$17.45/sh−50,000$872,500→ 17,720 total - Exercise/Conversion
Common Stock
2018-07-06$5.13/sh+25,000$128,250→ 42,720 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-07-06−25,000→ 0 totalExercise: $5.13From: 2015-10-29Exp: 2024-10-29→ Common Stock (25,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2018-07-06−25,000→ 0 totalExercise: $5.95From: 2016-10-27Exp: 2025-10-27→ Common Stock (25,000 underlying)
Holdings
- 45,000(indirect: See footnote)
Common Stock
Footnotes (2)
- [F1]The price reported for these shares is the weighted average sale price of transactions made at prices from $17.45 to $17.461. Details of actual prices for shares sold are available from the Issuer upon request.
- [F2]Comprised of 30,000 shares of common stock in trust for the benefit of Mr. Lefkoff's minor children and 15,000 shares of common stock held by BV Partners III Profit Sharing account for the benefit of Mr. Lefkoff.